NCT05149898View on ClinicalTrials.gov

Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 3, 2020

Primary Completion Date

November 21, 2022

Study Completion Date

November 21, 2022

Conditions
22Q Deletion Syndrome
Interventions
DRUG

ZYN002

"CBD Transdermal Gel pharmaceutically manufactured. Cannabidiol (CBD) formulated as a clear gel (transdermal delivery).~Dose received is based on weight.~1. Patients who weigh ≤ 35 kg will receive 125 mg CBD Q12H (every 12 hours); for a total daily dose of 250 mg CBD.~2. Patients who weigh \> 35 kg will receive 250 mg CBD Q12H (±2 hours); for a total daily dose of 500 mg CBD."

Trial Locations (3)

3161

Genetics Clinics Australia, Melbourne

4101

Lady Cilento Children's Hospital - South Brisbane, Brisbane

29605

Greenwood Genetic Center, Greenville

All Listed Sponsors
lead

Zynerba Pharmaceuticals, Inc.

INDUSTRY

NCT05149898 - Open-Label Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With 22q11.2 Deletion Syndrome | Biotech Hunter | Biotech Hunter